New Options for Treatment of RA and Lupus are Focus of Rheumatology Thought
Leader Panel
MedPredict Report Assesses New Data Presented at ACR 2009
SCOTTSDALE, Ariz., Nov. 6 /PRNewswire/ -- MedPredict Market Research, a global
provider of pharmaceutical competitive intelligence and market research, has
published a new report providing critical strategic insight for companies with
a stake in the market for rheumatology therapies, including rheumatoid
arthritis (RA) and lupus.
"Of all the diseases rheumatologists treat, lupus still has the highest unmet
need," according to MedPredict president Jeffrey Berk. "While many more
people have RA than have lupus, lupus kills, and RA doesn't. There are a
plethora of good therapies for RA, but few for lupus. This expert panel
weighs in on the leading B-cell inhibitors that are in development for lupus,
and provides insight into how different lupus trial designs have thus far
driven clinical outcomes."
To develop this analysis, entitled "Thought Leader Insight & Analysis:
Rheumatology," MedPredict conducted primary interviews with U.S.-based
rheumatology thought leaders around the time of the recent American College of
Rheumatology 2009 conference.
Some of the issues analyzed in this report:
-- Reactions to pivotal Phase III data supporting GlaxoSmithKline's
Benlysta (belimumab) in systemic lupus erythemetosis (SLE).
-- Impact of the FDA's complete response letter rejecting Genentech's
application for Rituxan (rituximab) in RA patients who have previously
failed DMARD therapy - do thought leaders think PML safety concerns
apply to all B-cell inhibitors?
-- Insight into rheumatologists' decision-making process for selecting
treatment for RA. How will anti-TNF newcomers fit into the
rheumatologist's armamentarium?
-- Role of other mechanisms, including CTLA4, IL-6, IL-17, JAK, Syk,
TNF/PDE4, BTK, MEK, and S1P.
Companies/Partnerships mentioned in this report include: Abbott, Alder,
Amgen/Pfizer, Arana, Array, AstraZeneca/MedImmune, Bristol-Myers Squibb,
Celgene, Centocor/Schering-Plough, Cytopia, Genentech/Roche,
Genentech/Roche/Chugai, GlaxoSmithKline/Genmab, GSK/Human Genome Sciences,
Incyte, Lexicon, Lilly, Merck, Merck Serono/ZymoGenetics, Novartis,
Pharmacyclics, Rigel, UCB, UCB/Immunomedics, Pfizer/Trubion.
This report can be purchased by contacting MedPredict.
About MedPredict
MedPredict (www.medpredict.com) maintains a proprietary database of over 1,000
global physician thought leaders, including 40+ specialties in 30+ therapeutic
categories. Based on primary interviews with these thought leaders,
MedPredict publishes periodic reports in each category to keep clients
up-to-date on emerging trends and competitive activity. The reports include
thought leader reactions to recent publications and medical conferences, as
well as clinical, regulatory and marketing activity.
SOURCE MedPredict
Elizabeth Mathews of MedPredict, +1-513-271-1924, liz@medpredict.com
